INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
INmune Bio Inc INMB
$2.03
▲ +1.50%
(+$0.03)
⬆️ Above Yest. High
Open
$2.01
Prev Close
$2.00
Day Range
$1.96 – $2.04
52W Range
$1.09 – $2.60
Market Cap
$56.34M
Beta
0.95
EPS (TTM)
$-0.69
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-02-04 |
| Shares Out. | 26,590,000 |
| Website | inmunebio.com/ ↗ |
| Phone | 18589643720 |
| Employees | 21 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.3M |
| Free Cash Flow | -$15.7M |
| Total Assets | $26.8M |
| Total Liabilities | $6.5M |
| Equity | $20.4M |
About INmune Bio Inc
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
INmune Bio Inc is a publicly traded company under the ticker symbol INMB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)